New Non Invasive Test For Detection Of Tumors Of The Colon Is More Accurate Than Previously Used

New Non Invasive Test For Detection Of Tumors Of The Colon Is More Accurate Than Previously Used.
A callow noninvasive evaluate to sense pre-cancerous polyps and colon tumors appears to be more accurate than advised noninvasive tests such as the fecal occult blood test, Mayo clinic researchers say. The pursuit for a highly accurate, noninvasive alternative to invasive screens such as colonoscopy or sigmoidoscopy is a "Holy Grail" of colon cancer research hgh up club. In a introduction trial, the new probe was able to identify 64 percent of pre-cancerous polyps and 85 percent of full-blown cancers, the researchers reported.

Dr Floriano Marchetti, an deputy professor of clinical surgery in the division of colon and rectal surgery at University of Miami Sylvester Comprehensive Cancer Center, said the untrodden prove could be an important adjunct to colon cancer screening if it proves itself in further study. "Obviously, these findings demand to be replicated on a larger scale sexual. Hopefully, this is a good start for a more reliable test".

Dr Durado Brooks, the man of colorectal cancer at the American Cancer Society, agreed. "These findings are interesting. They will be more enchanting if we ever get this kind of data in a screening population".

The study's lead researcher remained optimistic. "There are 150000 unfledged cases of colon cancer each year in the United States, treated at an estimated get of $14 billion," noted Dr David A Ahlquist, professor of c physic and a consultant in gastroenterology at the Mayo Clinic in Rochester, Minn. "The hallucinate is to eradicate colon cancer altogether and the most realistic approach to getting there is screening. And screening not only in a mode that would not only detect cancer, but pre-cancer. Our test takes us closer to that dream".

Ahlquist was scheduled to bring the findings of the study Thursday in Philadelphia at a meeting on colorectal cancer sponsored by the American Association for Cancer Research. The rejuvenated technology, called the Cologuard sDNA test, plant by identifying specific altered DNA in cells shed by pre-cancerous or cancerous polyps into the patient's stool.

If a DNA unusualness is found, a colonoscopy would still be needed to confirm the results, just as happens now after a convinced fecal occult blood test (FOBT) result. To see whether the test was effective, Ahlquist's band tried it out on more than 1100 frozen stool samples from patients with and without colorectal cancer.

The investigation was able to detect 85,3 percent of colorectal cancers and 63,8 percent of polyps bigger than 1 centimeter. Polyps this vastness are considered pre-cancers and most likely to progress to cancer.